These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26461913)

  • 1. Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography.
    Ishiki A; Okamura N; Furukawa K; Furumoto S; Harada R; Tomita N; Hiraoka K; Watanuki S; Ishikawa Y; Tago T; Funaki Y; Iwata R; Tashiro M; Yanai K; Kudo Y; Arai H
    PLoS One; 2015; 10(10):e0140311. PubMed ID: 26461913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
    Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
    Okamura N; Furumoto S; Harada R; Tago T; Yoshikawa T; Fodero-Tavoletti M; Mulligan RS; Villemagne VL; Akatsu H; Yamamoto T; Arai H; Iwata R; Yanai K; Kudo Y
    J Nucl Med; 2013 Aug; 54(8):1420-7. PubMed ID: 23857514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.
    Leinonen V; Rauramaa T; Johansson J; Bottelbergs A; Tesseur I; van der Ark P; Pemberton D; Koivisto AM; Jääskeläinen JE; Hiltunen M; Herukka SK; Blennow K; Zetterberg H; Jokinen P; Rokka J; Helin S; Haaparanta-Solin M; Solin O; Okamura N; Kolb HC; Rinne JO
    J Alzheimers Dis; 2018; 64(1):171-179. PubMed ID: 29865068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease.
    Harada R; Okamura N; Furumoto S; Furukawa K; Ishiki A; Tomita N; Hiraoka K; Watanuki S; Shidahara M; Miyake M; Ishikawa Y; Matsuda R; Inami A; Yoshikawa T; Tago T; Funaki Y; Iwata R; Tashiro M; Yanai K; Arai H; Kudo Y
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1052-61. PubMed ID: 25792456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.
    Lockhart SN; Baker SL; Okamura N; Furukawa K; Ishiki A; Furumoto S; Tashiro M; Yanai K; Arai H; Kudo Y; Harada R; Tomita N; Hiraoka K; Watanuki S; Jagust WJ
    PLoS One; 2016; 11(6):e0158460. PubMed ID: 27355840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverging Relationships among Amyloid, Tau, and Brain Atrophy in Early-Onset and Late-Onset Alzheimer's Disease.
    Na HK; Shin JH; Kim SW; Seo S; Kim WR; Kang JM; Lee SY; Cho J; Byun J; Okamura N; Seong JK; Noh Y
    Yonsei Med J; 2024 Aug; 65(8):434-447. PubMed ID: 39048319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain.
    Cai L; Qu B; Hurtle BT; Dadiboyena S; Diaz-Arrastia R; Pike VW
    ACS Chem Neurosci; 2016 Jul; 7(7):897-911. PubMed ID: 27171905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau positron emission tomography using [
    Kang JM; Lee SY; Seo S; Jeong HJ; Woo SH; Lee H; Lee YB; Yeon BK; Shin DH; Park KH; Kang H; Okamura N; Furumoto S; Yanai K; Villemagne VL; Seong JK; Na DL; Ido T; Cho J; Lee KM; Noh Y
    Neurobiol Aging; 2017 Nov; 59():210-219. PubMed ID: 28890300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease.
    Colato E; Chiotis K; Ferreira D; Mazrina MS; Lemoine L; Mohanty R; Westman E; Nordberg A; Rodriguez-Vieitez E;
    J Alzheimers Dis; 2021; 84(1):103-117. PubMed ID: 34511502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology.
    Harada R; Okamura N; Furumoto S; Tago T; Maruyama M; Higuchi M; Yoshikawa T; Arai H; Iwata R; Kudo Y; Yanai K
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):125-32. PubMed ID: 23100049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Comparison of Tau Radioligands
    Betthauser TJ; Lao PJ; Murali D; Barnhart TE; Furumoto S; Okamura N; Stone CK; Johnson SC; Christian BT
    J Nucl Med; 2017 Jun; 58(6):996-1002. PubMed ID: 27856627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Evaluation of [(18)F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer.
    Tago T; Furumoto S; Okamura N; Harada R; Adachi H; Ishikawa Y; Yanai K; Iwata R; Kudo Y
    Mol Imaging Biol; 2016 Apr; 18(2):258-66. PubMed ID: 26194011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue.
    Lemoine L; Saint-Aubert L; Marutle A; Antoni G; Eriksson JP; Ghetti B; Okamura N; Nennesmo I; Gillberg PG; Nordberg A
    Acta Neuropathol Commun; 2015 Jul; 3():40. PubMed ID: 26134112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.
    Harada R; Okamura N; Furumoto S; Furukawa K; Ishiki A; Tomita N; Tago T; Hiraoka K; Watanuki S; Shidahara M; Miyake M; Ishikawa Y; Matsuda R; Inami A; Yoshikawa T; Funaki Y; Iwata R; Tashiro M; Yanai K; Arai H; Kudo Y
    J Nucl Med; 2016 Feb; 57(2):208-14. PubMed ID: 26541774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.
    Wren MC; Lashley T; Årstad E; Sander K
    Acta Neuropathol Commun; 2018 May; 6(1):34. PubMed ID: 29716656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351.
    Oh M; Oh SJ; Lee SJ; Oh JS; Roh JH; Chung SJ; Lee JH; Lee CS; Kim JS
    Clin Nucl Med; 2020 Nov; 45(11):841-847. PubMed ID: 32910050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau imaging with [
    Ishiki A; Harada R; Okamura N; Tomita N; Rowe CC; Villemagne VL; Yanai K; Kudo Y; Arai H; Furumoto S; Tashiro M; Furukawa K
    Eur J Neurol; 2017 Jan; 24(1):130-136. PubMed ID: 27797445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer's disease.
    Kim M; Kim SJ; Park JE; Yun J; Shim WH; Oh JS; Oh M; Roh JH; Seo SW; Oh SJ; Kim JS
    Sci Rep; 2021 May; 11(1):10343. PubMed ID: 33990649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease.
    Leuzy A; Rodriguez-Vieitez E; Saint-Aubert L; Chiotis K; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Alzheimers Dement; 2018 May; 14(5):652-663. PubMed ID: 29268078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.